Oragenics, Inc. (OGEN)
USD 0.26
(-3.51%)
USD 0.26
(-3.51%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | - USD | 0.0% |
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | -100.0% |
| 2015 | 321.5 Thousand USD | -26.79% |
| 2014 | 439.18 Thousand USD | 52.29% |
| 2013 | 288.38 Thousand USD | 132.23% |
| 2012 | 124.17 Thousand USD | -73.89% |
| 2011 | 475.59 Thousand USD | 78.37% |
| 2010 | 266.62 Thousand USD | 101.82% |
| 2009 | 132.11 Thousand USD | 1018.27% |
| 2008 | 11.81 Thousand USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - USD | 0.0% |
| 2024 Q2 | - USD | 0.0% |
| 2023 Q4 | - USD | 0.0% |
| 2023 FY | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q1 | -6987.00 USD | 0.0% |
| 2022 Q3 | -6987.00 USD | 0.0% |
| 2022 FY | - USD | 0.0% |
| 2022 Q4 | - USD | 100.0% |
| 2022 Q2 | - USD | 100.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | -100.0% |
| 2016 Q1 | 241.48 Thousand USD | -24.89% |
| 2016 Q2 | - USD | -100.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 Q2 | 364.07 Thousand USD | -3.43% |
| 2015 FY | 321.5 Thousand USD | -26.79% |
| 2015 Q4 | 321.5 Thousand USD | 7.41% |
| 2015 Q3 | 299.31 Thousand USD | -17.79% |
| 2015 Q1 | 377.01 Thousand USD | -14.16% |
| 2014 Q1 | 265.88 Thousand USD | -7.8% |
| 2014 Q2 | 238.97 Thousand USD | -10.12% |
| 2014 FY | 439.18 Thousand USD | 52.29% |
| 2014 Q4 | 439.18 Thousand USD | 66.45% |
| 2014 Q3 | 263.86 Thousand USD | 10.41% |
| 2013 FY | 288.38 Thousand USD | 132.23% |
| 2013 Q4 | 288.38 Thousand USD | 29.14% |
| 2013 Q3 | 223.31 Thousand USD | -26.3% |
| 2013 Q1 | 117.26 Thousand USD | -5.57% |
| 2013 Q2 | 303 Thousand USD | 158.39% |
| 2012 Q4 | 124.17 Thousand USD | -55.64% |
| 2012 Q2 | 353.82 Thousand USD | -2.52% |
| 2012 Q1 | 362.98 Thousand USD | -23.68% |
| 2012 FY | 124.17 Thousand USD | -73.89% |
| 2012 Q3 | 279.94 Thousand USD | -20.88% |
| 2011 Q2 | 500.56 Thousand USD | 82.01% |
| 2011 FY | 475.59 Thousand USD | 78.37% |
| 2011 Q1 | 275.01 Thousand USD | 3.15% |
| 2011 Q3 | 465.47 Thousand USD | -7.01% |
| 2011 Q4 | 475.59 Thousand USD | 2.17% |
| 2010 Q1 | 278.42 Thousand USD | 110.75% |
| 2010 FY | 266.62 Thousand USD | 101.82% |
| 2010 Q4 | 266.62 Thousand USD | -28.6% |
| 2010 Q3 | 373.42 Thousand USD | -10.34% |
| 2010 Q2 | 416.47 Thousand USD | 49.58% |
| 2009 Q4 | 132.11 Thousand USD | 15.77% |
| 2009 FY | 132.11 Thousand USD | 1018.27% |
| 2009 Q1 | 64.84 Thousand USD | 448.87% |
| 2009 Q2 | 42.8 Thousand USD | -33.99% |
| 2009 Q3 | 114.11 Thousand USD | 166.6% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | 11.81 Thousand USD | 0.0% |
| 2008 Q4 | 11.81 Thousand USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -1.18 Million USD | 100.0% |
| Ampio Pharmaceuticals, Inc. | 1.00 USD | 100.0% |
| Armata Pharmaceuticals, Inc. | - USD | NaN% |
| Actinium Pharmaceuticals, Inc. | - USD | NaN% |
| Azitra, Inc. | -215.21 Thousand USD | 100.0% |
| Can-Fite BioPharma Ltd. | - USD | NaN% |
| Chromocell Therapeutics Corporation | - USD | NaN% |
| Calidi Biotherapeutics, Inc. | - USD | NaN% |
| CEL-SCI Corporation | 2.24 Million USD | 100.0% |
| iBio, Inc. | - USD | NaN% |
| Lineage Cell Therapeutics, Inc. | - USD | NaN% |
| MAIA Biotechnology, Inc. | - USD | NaN% |
| Matinas BioPharma Holdings, Inc. | - USD | NaN% |
| Navidea Biopharmaceuticals, Inc. | 427.34 Thousand USD | 100.0% |
| NovaBay Pharmaceuticals, Inc. | 2.87 Million USD | 100.0% |
| NanoViricides, Inc. | - USD | NaN% |
| BiomX Inc. | - USD | NaN% |
| BiomX Inc. | - USD | NaN% |
| Protalix BioTherapeutics, Inc. | 19.04 Million USD | 100.0% |
| Palatin Technologies, Inc. | - USD | NaN% |
| Scorpius Holdings, Inc. | 909.15 Thousand USD | 100.0% |